摘要
目的 探讨分析XELOX化疗方案联合沙利度胺治疗结直肠癌的疗效及对肿瘤异常蛋白(TAP)、家族性腺瘤样息肉病蛋白(APC)的影响。方法 选择2016年1月至2018年1月在本院进行治疗的124例结直肠癌患者作为研究对象,根据随机数字表法分为对照组和观察组,每组62例;对照组给予XELOX化疗方案,观察组在此基础上给予沙利度胺治疗;比较两组患者治疗效果,治疗前后血清肿瘤标志物变化、TAP以及APC水平变化,同时观察比较两组患者不良反应发生情况。结果 观察组有效率显著高于对照组,差异有统计学意义(P<0.05);治疗后,观察组CD8+水平显著低于对照组,而CD3+、CD4+和CD4+/CD8+水平显著高于对照组,差异均有统计学意义(均P<0.05);治疗后观察组TAP阳性表达率显著低于对照组,APC蛋白阳性表达率显著高于对照组,差异均有统计学意义(均P<0.05);两组不良反应发生率相近,差异无统计学意义(P>0.05)。结论 XELOX化疗方案联合沙利度胺能明显改善结直肠癌患者的治疗效果,而且安全性较高,值得在临床广泛应用。
Objective To investigate the efficacy of XELOX chemotherapy combined with thalidomide in the treatment of rectal cancer and the effect on tumor abnormal protein(TAP)and adenomatous polyposis col(APC)proteins.Methods A total of124patients with rectal cancer treated at our hospital from January,2016to January,2018were selected and randomly divided into a control group and an observation group using random number table method,62for each group.The control group were treated with XELOX chemotherapy,and the observation group with XELOX chemotherapy and thalidomide.The treatment effects,the levels of serum tumor markers,TAP,and APC before and after treatment were compared between the two groups.And the incidence of adverse reactions was compared between the two groups.Results The effective rate was significantly in the observation group than in the control group,with a statistical difference(P<0.05).After the treatment,the CD8+level was significantly lower and the levels of CD3+,CD4+,and CD4+/CD8+were significantly higher in the observation group than in the control group,with statistical differences(all P<0.05).After the treatment,the positive expression rate of TAP was significantly lower and the positive expression rate of APC protein was significantly higher in the observation group than in the control group,with statistical differences(both P<0.05).There was no statistical difference in the incidence of adverse reactions between these two groups(P>0.05).Conclusion XELOX chemotherapy combined with thalidomide for patients with colorectal cancer can significantly improve the efficacy and is safe,so it is worth being clinically generalized.
作者
杨志国
刘增福
Yang Zhiguo;Liu Zengfu(Department of Oncology,Heze Municipal Hospital, Heze 274000, China;Department of Gastroenterology,Heze Municipal Hospital, Heze 274000, China)
出处
《国际医药卫生导报》
2018年第18期2769-2773,共5页
International Medicine and Health Guidance News
